Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 37(1): 34-38, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34665475
ABSTRACT
The microbiome has revolutionized the field of cancer immunology and checkpoint therapeutics for gastrointestinal malignancies. Combating hepatocellular carcinoma (HCC) by immune checkpoint blockade (ICB) is a unique challenge due in part to chronic complications that arise from local and systemic metabolic dysfunctions. Gut microbial metabolites modulate key immunological processes that influence liver cancer susceptibility and resistance to ICB. This review discusses recent progresses in linking microbiota functions to HCC tumor immunity and highlights their therapeutic potential.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Hepatocelular
/
Imunoterapia
/
Neoplasias Hepáticas
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article